Monte Rosa Therapeutics (GLUE) Current Leases (2022 - 2026)

Monte Rosa Therapeutics' Current Leases history runs 5 years deep, the most recent figure standing at $4.5 million for Q1 2026.

• On a quarterly basis, Current Leases rose 15.99% year-over-year to $4.5 million in Q1 2026; TTM through Mar 2026 was $4.5 million, a 15.99% increase from a year earlier, with the FY2025 full-year figure at $4.4 million, up 18.39% from the prior year.
• Current Leases advanced to $4.5 million in Q1 2026 per GLUE's latest filing, from $4.4 million in the prior quarter.
• Across five years, Current Leases topped out at $4.5 million in Q1 2026 and bottomed at $2.7 million in Q2 2022.
• The 5-year median for Current Leases is $3.4 million (2024), against an average of $3.5 million.
• Across the five-year window, Current Leases slipped 6.0% in 2023 and jumped 30.15% in 2024, its largest moves.
• Year by year, Current Leases stood at $3.1 million in 2022, then increased by 1.12% to $3.2 million in 2023, then increased by 17.46% to $3.7 million in 2024, then grew by 18.39% to $4.4 million in 2025, then rose by 1.96% to $4.5 million in 2026.
• Per Business Quant, the three latest GLUE Current Leases figures stand at $4.5 million (Q1 2026), $4.4 million (Q4 2025), and $4.2 million (Q3 2025).